**Full Board**

* A project that involves greater than minimal risk (see definition, below) requires approval by an IRB panel, the Board, composed of members qualified to review research in that field. The Board meets once per month.
* Deadlines for IRB applications requiring Full IRB Review generally are the 2nd Monday of the month for the upcoming month’s IRB meeting.
* IRB approval will be granted for a determined length of time not to exceed one year. The IRB approval expiration date will be specified in the approval letter.
* Continuing review is required for re-approval if the research is to continue beyond the expiration date. The continuing review request must be reviewed by the Full IRB at its monthly meeting unless one of the following applies: 1) the research is permanently closed to the enrollment of new subjects; all subjects have completed all research related interventions; and the research remains active only for long-term follow-up of subjects; or 2) where no subjects have been enrolled and no additional risks have been identified; or 3) where the remaining research activities are limited to data analysis; or 4) continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories for expedited approval do not apply, but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.
* Unless waived by the IRB, signed consent must be obtained from all subjects prior to their involvement in the research.
* The IRB holds the authority to recommend or require modifications to submitted IRB materials at any time.
* Modifications to or additions/deletions of human subject research-related documents (including the research protocol) must be approved by the IRB prior to implementation (except where necessary to eliminate apparent immediate hazards to subjects).
* It is the researchers' responsibility to report promptly to the IRB any injuries or other unanticipated or adverse events involving risks or harms to human research subjects or others.
* The Board's decision to contingently approve, table, or disapprove a protocol will be communicated to the investigators via mail, which will specify the reasons for the decision and proposed actions/revisions, as applicable.
* Once approved, involved researchers are notified of the Full IRB approval via an official approval letter sent via e-mail or mail.

Research that requires full committee review may include one or more of the following:

* Prisoners
* Pregnant Women
* Fetuses
* Human in Vitro Fertilization
* Mentally Disabled Persons
* Microwaves or X-Rays
* General Anesthesia or Sedation
* Poses greater than minimal risks to subjects (unless qualifying for Exempt review)
* Vulnerable Populations

This list is not exhaustive. The final decision as to whether an application is reviewed by the Board at a convened meeting is that of the IRB Chair and/or Board.